View Filing Data

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Jun. 30, 2015	Aug. 14, 2015
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Trading Symbol	hsm
Entity Registrant Name	HELIUS MEDICAL TECHNOLOGIES, INC.
Entity Central Index Key	0001610853
Current Fiscal Year End Date	--03-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		64,969,775
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q1

Interim Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2015	Mar. 31, 2015
Current assets
Cash and cash equivalents	$ 971,863	$ 418,893
Short-term investment	0	378,000
Receivables	24,231	8,833
Prepaid expenses	434,245	410,621
Total current assets	1,430,339	1,216,347
TOTAL ASSETS	1,430,339	1,216,347
Current liabilities
Accounts payable and accrued liabilities	1,583,499	1,197,804
Total current liabilities	1,583,499	1,197,804
Derivative liability	1,846,083	1,581,444
TOTAL LIABILITIES	3,429,582	2,779,248
CAPITAL DEFICIT
Common stock (Unlimited Class A common shares authorized); (64,303,924 shares outstanding at June 30, 2015 and 63,104,788 shares outstanding at March 31, 2015)	18,792,322	16,358,093
Additional paid-in capital	1,713,992	1,490,790
Shares to be issued	0	39,545
Accumulated other comprehensive income	(931,014)	(971,640)
Accumulated deficit	(21,574,543)	(18,479,689)
TOTALCAPITAL DEFICIT	(1,999,243)	(1,562,901)
TOTAL LIABILITIES & CAPITAL DEFICIT	$ 1,430,339	$ 1,216,347

Interim Condensed Consolidated Statements of Comprehensive Loss - USD ($)	3 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Operating Expenses
Advertising, marketing & investor relations	$ 308,213	$ 46,226
Audit & accounting	80,462	10,645
Consulting fees	142,822	200,849
Insurance	29,539	7,486
Legal fees	293,736	219,934
Meals & travel	95,867	29,441
Office & general	26,039	21,424
Professional fees	0	13,125
Research & development	1,386,676	653,259
Transfer agent & regulatory	32,579	15,260
Wages and salaries	439,065	170,981
Loss from operations	(2,834,998)	(1,388,630)
Other items
Interest expense	(53)	(176,488)
Interest income	0	2,810
Change in fair value of derivative liability	(178,378)	0
Foreign exchange loss	(81,425)	(6,446)
Total other items	(259,856)	(180,124)
Net loss for the period	(3,094,854)	(1,568,754)
Other comprehensive income
Translation adjustments	40,626	106,059
Comprehensive loss for the period	$ (3,054,228)	$ (1,462,695)
Basic and diluted loss per common stock	$ (0.05)	$ (0.04)
Weighted average number of common stock outstanding - basic & diluted	63,722,378	38,812,706

Interim Condensed Consolidated Statements of Capital Equity (Deficit) - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Shares to be Issued [Member]	Accumulated Deficit [Member]	Accumulated other comprehensive income (loss)[Member]	Total
Beginning Balance at Mar. 31, 2014	$ 8,510,000	$ 807,157		$ (9,585,134)		$ (267,977)
Beginning Balance (Shares) at Mar. 31, 2014	32,070,052
Stock-based compensation on 2,300,000 options granted		50,303				50,303
Shares issued to consultant for option exercise 1	$ 717					717
Shares issued to consultant for option exercise 1 (Shares)	2,300,000
Shares issued to consultant for option exercise 2	$ 290					290
Shares issued to consultant for option exercise 2 (Shares)	930,031
Fair value of options allocated to share capital on exercise of options	$ 857,460	(857,460)
Recapitalization of Helius Medical Technologies, Inc.		162,890				162,890
Recapitalization of Helius Medical Technologies, Inc. (Shares)	10,000,000
Issuance of common stock for private placement	$ 6,437,041	578,961				7,016,002
Issuance of common stock for private placement (Shares)	15,240,000
Share issuance cost	$ (447,515)	67,709				(379,806)
Stock-based compensation on 2,570,000 options granted		283,962				283,962
Beneficial conversion feature		176,488				176,488
Conversion of debenture	$ 1,000,100					1,000,100
Conversion of debenture (Shares)	2,564,705
Stock-based compensation on 100,000 options granted 1		74,190				74,190
Stock-based compensation on 100,000 options granted 2		43,229				43,229
Stock-based compensation on 400,000 options granted		135,564				135,564
Stock-based compensation on 100,000 options granted 3		41,987				41,987
Fair value of vested non-employee options reallocated to derivative liability		(74,190)				(74,190)
Private placement proceeds			$ 39,545			39,545
Net loss for the period				(8,894,555)		(8,894,555)
Translation adjustments					$ (971,640)	(971,640)
Ending Balance at Mar. 31, 2015	$ 16,358,093	1,490,790	39,545	(18,479,689)	(971,640)	(1,562,901)
Ending Balance (Shares) at Mar. 31, 2015	63,104,788
Exercise of finders warrants	$ 11,926					11,926
Exercise of finders warrants (Shares)	14,400
Issuance of common stock for private placement	$ 1,825,937					1,825,937
Issuance of common stock for private placement (Shares)	849,273
Issuance of common stock for private placement 2	$ 721,243		$ (39,545)			681,698
Issuance of common stock for private placement 2 (Shares)	335,463
Share issuance cost	$ (124,877)					(124,877)
Stock-based compensation on 2,570,000 options granted		173,899				173,899
Stock-based compensation on 400,000 options granted		135,564				135,564
Fair value of vested non-employee options reallocated to derivative liability		(86,261)				(86,261)
Net loss for the period				(3,094,854)		(3,094,854)
Translation adjustments					40,626	40,626
Ending Balance at Jun. 30, 2015	$ 18,792,322	$ 1,713,992		$ (21,574,543)	$ (931,014)	$ (1,999,243)
Ending Balance (Shares) at Jun. 30, 2015	64,303,924

Interim Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities
Net loss for the period	$ (3,094,854)	$ (1,568,754)
Items not involving cash:
Change in fair value of derivative liability	178,378	0
Stock-based compensation	309,463	338,291
Accretion	0	176,488
Changes in non-cash working capital items:
Receivables	(15,264)	0
Prepaid expenses	(22,205)	(108,895)
Accounts payable and accrued liabilities	382,844	622,002
Foreign exchange re-measurement	115,638	0
Net cash used in operating activities	(2,146,000)	(540,868)
Cash flows from investing activities
Short-term investment	378,000	0
Cash acquired on recapitalization	0	23,904
Proceeds from bridge loan	0	150,000
Net cash provided by investing activities	378,000	173,904
Cash flows from financing activities
Proceeds from the issuance of shares	2,519,561	6,607,402
Share issuance cost	(124,877)	0
Proceeds from the issuance of convertible debt	0	633,195
Net cash provided by financing activities	2,394,684	7,240,597
Effect of foreign exchange rate changes on cash	(73,714)	140,658
Net change in cash	552,970	7,014,291
Cash, beginning of the period	418,893	15,968
Cash, end of the period	971,863	7,030,259
Supplemental cash flow information
Interest paid in cash	0	0
Income taxes paid in cash	$ 0	$ 0

SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Jun. 30, 2015

SIGNIFICANT ACCOUNTING POLICIES [Text Block]

2.	SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Liquidity

The Company has incurred a net loss of $3,094,854 for the three months ended June 30, 2015 (June 30, 2014 - $1,568,754) and, as of June 30, 2015, the Company has an accumulated deficit of $21,574,543 (March 31, 2015 - $18,479,689). Until the Company generates a level of revenue to support its cost structure, the Company expects to continue to incur substantial operating losses and net cash outflows. While the Company had cash and cash equivalents of $971,863 as of June 30, 2015 (March 31, 2015 - $418,893), management does not believe these resources will be sufficient to meet the Company’s operating and capital needs for the ensuing fiscal year.

The Company intends to fund ongoing activities by utilizing current cash and cash equivalents and by raising additional capital through equity or debt financings. There can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company. If the Company is unable to raise sufficient additional capital, the Company may be compelled to reduce the scope of its operations and planned capital expenditure or sell certain assets, including intellectual property assets. This material uncertainty gives rise to substantial doubt about the Company’s ability to continue as a going concern.

Fair Value of Financial Assets and Liabilities

The Company’s financial instruments consist primarily of cash and cash equivalents and accounts payable and accrued liabilities. The book values of these instruments approximate their fair values due to the immediate or short-term nature of those instruments.

ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value;

Level 1 – Quoted prices in active markets for identical assets or liabilities;

Level 2 – Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and

Level 3 – Unobservable inputs that are supported by little or no market activity, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.

Cash and cash equivalents and short-term investment are measured using Level 1 inputs.

The Company had certain Level 3 liabilities required to be recorded at fair value on a recurring basis in accordance with US GAAP as at June 30, 2015. As at June 30, 2015, the Company’s Level 3 liabilities consisted of the grant of share Purchase options to non-employees. The resulting Level 3 liabilities have no active market and are required to be measured at their fair value each reporting period based on information that is unobservable.

A summary of the Company’s Level 3 liabilities for the periods ended June 30, 2015 and March 31, 2015 are as follows:

	Three months ended June 30, 2015	Year ended March 31, 2015
	$	$

Non-employee options (Note 5(a))
Beginning fair value	1,581,444	-
Issuance	-	767,879
Reallocation of vested non-employee options	86,261	74,190
Change in fair value	178,378	739,375
Ending fair value of Level 3 liability	1,846,083	1,581,444

Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances (for example, when there is evidence of impairment). There were no assets or liabilities measured at fair value on a nonrecurring basis during the periods ended June 30, 2015 and 2014.

Recent Accounting Pronouncements

In April 2015, the FASB issued Accounting Standards Update No. 2015-03 Interest – Imputation of Interest (Subtopic 835-30). This guidance is to simplify the presentation of debt issuance costs by recognizing debt issuance costs in the balance sheet as a direct deduction from that debt liability consistent with the presentation of a debt discount. The amendments in this Update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The Company is currently evaluating the impact of adoption of this new accounting pronouncement on its financial statements.

COMMON STOCK

3 Months Ended

Jun. 30, 2015

COMMON STOCK [Text Block]

4.	COMMON STOCK

Authorized:

Unlimited Class A common shares without par value.

Each Class A common share is entitled to have the right to vote at any shareholder meeting on the basis of one vote per share. Each Class A share held entitles the holder to receive dividends as declared by the directors. In the event of the liquidation, dissolution or winding-up of the Company other distribution of assets of the Company among its shareholders for the purposes of winding-up its affairs or upon a reduction of capital the holders of the Class A common shares shall, share equally, share for share, in the remaining assets and property of the Company.

Class B common shares and Class A preferred shares were deleted from the list of classes of shares the Company is authorized to issue by way of amendment to the Company’s articles effective June 12, 2014.

The Company is subject to a stockholders agreement, which places certain restrictions on the Company’s stock and its stockholders. These restrictions include approvals prior to sale or transfer of stock, a right of first refusal to purchase stock held by the Company and a secondary right of refusal to stockholders, right of co-sale whereby certain stockholders may be enabled to participate in a sale of other stockholders to obtain the same price, term and conditions on a pro-rata basis, rights of first offer of new security issuances to current stockholders on a pro-rata basis and certain other restrictions.

On April 30, 2015 the Company closed a non-brokered private placement (the “First Financing”) raising gross proceeds of $1,825,937 by the issuance of 849,273 units (each a “First Financing Unit”) at a price of $2.15 per First Financing Unit. Each First Financing Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a “First Financing Warrant”). Each whole First Financing Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $3.00 per share for a period of thirty-six (36) months from the closing date of the Financing. The Company paid a cash finder’s fee of $84,074 in connection with this First Financing, as well as 27,396 finder’s warrants (the “First Financing Finder’s Warrants”). Each First Financing Finder’s Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $3.00 per share for a period of thirty-six (36) months from the closing date of the First Financing.

On June 26, 2015 the Company closed a non-brokered private placement (the “Second Financing”) raising gross proceeds of $721,243 by the issuance of 335,463 units (each a “Second Financing Unit”) at a price of $2.15 per Second Financing Unit. Each Second Financing Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a “Second Financing Warrant”). Each whole Second Financing Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $3.00 per share for a period of thirty-six (36) months from the closing date of the Second Financing. The Company paid a cash finder’s fee of $40,803 in connection with this Second Financing, as well as 18,978 finder’s warrants (the “Second Financing Finder’s Warrants”). Each Second Financing Finder’s Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $2.15 per share for a period of sixty (60) months from the closing date of the Second Financing.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

SHARE BASED PAYMENTS

3 Months Ended

Jun. 30, 2015

SHARE BASED PAYMENTS [Text Block]

5.	SHARE BASED PAYMENTS

(a)	Stock options

The Company has a stock option plan whereby the Company is authorized to grant up to 12,108,016 options. Vesting and the term of an option is determined at the discretion of the Board of Directors of the Company.

The continuity of stock options for the periods as at June 30 and March 31, 2015, are as follows:

			Weighted
			Average		Aggregate
			Exercise Price		Intrinsic Value
	Number		(CAD)		(CAD)

Balance outstanding at March 31, 2015	4,920,000	$	1.14	$	10,120,000

Balance outstanding at June 30, 2015	4,920,000	$	1.14	$	6,676,000

Balance exercisable at June 30, 2015	3,319,587	$	1.16	$	4,435,212

The options outstanding and exercisable at June 30, 2015 are as follows:

		Options
		outstanding
		remaining
		contractual life		Exercise		Grant date fair	Number of options
Number of options	Expiry date	(years)		Price (CAD)		value (CAD)	exercisable

3,520,000	June 18, 2019	3.97	$	0.60	$	0.23	2,346,669
250,000	June 20, 2019	3.98	$	0.60	$	0.23	156,250
100,000	July 14, 2017	2.04	$	2.52	$	1.06	100,000
450,000	December 8, 2019	4.44	$	2.92	$	1.65	450,000
100,000	December 8, 2019	4.44	$	2.92	$	1.49	33,334
400,000	December 8, 2019	4.44	$	2.96	$	1.56	200,000
100,000	March 16, 2020	4.72	$	3.20		$1.61	33,334
4,920,000							3,319,587

The weighted average grant date fair value of stock options vested during the period ended June 30, 2015 of CAD$0.54 was estimated using the Black-Scholes option pricing model with the following weighted average assumptions: stock price – CAD$1.06 ; exercise price – CAD$1.14 ; expected risk-free interest rate – 1.08%; expected life – 4.1 years; expected volatility – 67.85% and expected dividend rate – 0%. The Company has adopted the simplified method prescribed by the SEC in SAB Topic 14 in respect of estimating the expected term of its stock options as its limited share purchase option history does not provide a reasonable basis to estimate the expected terms. Expected volatility was determined by reference to the average volatility rates of other companies in the same industry due to the Company’s limited trading history.

Non-Employee Stock Options

In accordance with the guidance of ASC 815-40-15, stock options awarded to non-employees that are performing services for Neuro are required to be accounted for as derivative liabilities once the services have been performed and the options have vested because they are considered not to be indexed to the Company’s stock due to their exercise price being denominated in a currency other than Neuro’s functional currency. Stock options awarded to non-employees that are not vested are accounted for as equity awards until the terms associated with their vesting requirements have been met.

The non-employee stock options are accounted for at their respective fair values and are summarized as follows for the three months ended June 30, 2015 and year ended March 31, 2015:

	Three months ended June 30, 2015	Year ended March 31, 2015
	$	$

Fair value of non-employee options, beginning of the period	1,581,444	-
Issuance	-	767,879
Reallocation of vested non-employee options	86,261	74,190
Change in fair value of non-employee stock options during the period	178,378	739,375

Fair value of non-employee options, end of the period	1,846,083	1,581,444

The non-employee options are required to be re-valued with the change in fair value of the liability recorded as a gain or loss on the change of fair value of derivative liability and included in other items in the Company’s Consolidated Statements of Loss at the end of each reporting period. The fair value of the options will continue to be classified as a liability until such time as they are exercised, expire or there is an amendment to the respective agreements that renders these financial instruments to be no longer classified as a liability.

Share-based payments are classified in the Company’s Statement of Loss as follows for the period ended June 30, 2015 and 2014:

	June 30, 2015	June 30, 2014
	$	$

Consulting fees	85,330	193,698
Research and development	-	50,303
Wages and salaries	224,133	94,290

	309,463	338,291

The Company used the Black Scholes option pricing model to estimate the fair value of the options as the fair value of the services provided could not be reliably calculated. The following assumptions were used:

		March 31, 2015	March 31, 2014
Stock Price	CAD$	0.50 – 3.18	0.27
Exercise Price	CAD$	0.60 – 3.20	0.0003
Risk-free interest rate (%)		0.53 – 1.42	1.20 – 1.65
Dividend yield (%)		0.00	0.00
Expected volatility (%)		67.85	97.73 – 116.82
Expected option life (years)		3.00 – 5.00	4.33 – 5.00

The Black Scholes option pricing model was developed for use in estimating the fair value of share options that have no vesting provisions and are fully transferable. Also, option-pricing models require the use of estimates and assumptions including the expected volatility. The Company uses expected volatility rates which are based upon the average volatility rates of other companies in the same industry, due to the Company’s limited history. The Company based the current stock price on the value per shares issued to date. Changes in the underlying assumptions can materially affect the fair value estimates.

(b)	Share Purchase Warrants

The Company closed its First Financing at $2.15 per First Financing Unit of 849,273 First Financing Units raising $1,825,937 on April 30, 2015. Each First Financing Unit consists of one common stock of the Company and one half of a First Financing Warrant of the Company where one full First Financing Warrant is exercisable for 3 years at $3.00 into one common share. The Company also issued 27,396 First Financing Finder’s Warrants. Each First Financing Finder’s Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $3.00 per share for a period of thirty-six (36) months from the closing date of the First Financing.

The Company closed its Second Financing at $2.15 per Second Financing Unit of 335,463 Second Financing Units raising $721,243 on June 26, 2015. Each Second Financing Units consists of one common stock of the Company and one half of a Second Financing Warrant of the Company where one full Second Financing Warrant is exercisable for 3 years at $3.00 into one common share. The Company also issued 18,978 Second Financing Finder’s Warrants. Each Second Financing Finder’s Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $2.15 per share for a period of sixty (60) months from the closing date of the Second Financing.

The continuity of warrants for the three months ended June 30, 2015 is as follows:

	Number of warrants				Weighted Average Exercise Price
	CAD		US		CAD $	US $
Balance, March 31, 2015	8,444,400		-	$	1.00	-
Granted	-		638,741	$	-	2.97
Exercised	(14,400	)	-	$	1.00	-
Balance, June 30, 2015	8,430,000		638,741	$	1.00	2.97

The warrants outstanding and exercisable at June 30, 2015 are as follows:

Number of warrants outstanding	Exercise Price	Expiry Date
8,430,000	CAD $1.00	May 30, 2016
452,032	US $3.00	April 30, 2018
167,731	US $3.00	June 26, 2018
18,978	US $2.15	June 26, 2020

SHARE BASED PAYMENTS (Tables)

3 Months Ended

Jun. 30, 2015

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

			Weighted
			Average		Aggregate
			Exercise Price		Intrinsic Value
	Number		(CAD)		(CAD)

Balance outstanding at March 31, 2015	4,920,000	$	1.14	$	10,120,000

Balance outstanding at June 30, 2015	4,920,000	$	1.14	$	6,676,000

Balance exercisable at June 30, 2015	3,319,587	$	1.16	$	4,435,212

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

		Options
		outstanding
		remaining
		contractual life		Exercise		Grant date fair	Number of options
Number of options	Expiry date	(years)		Price (CAD)		value (CAD)	exercisable

3,520,000	June 18, 2019	3.97	$	0.60	$	0.23	2,346,669
250,000	June 20, 2019	3.98	$	0.60	$	0.23	156,250
100,000	July 14, 2017	2.04	$	2.52	$	1.06	100,000
450,000	December 8, 2019	4.44	$	2.92	$	1.65	450,000
100,000	December 8, 2019	4.44	$	2.92	$	1.49	33,334
400,000	December 8, 2019	4.44	$	2.96	$	1.56	200,000
100,000	March 16, 2020	4.72	$	3.20		$1.61	33,334
4,920,000							3,319,587

Schedule of Non-Employee Share-based Compensation Arrangements Fair Values [Table Text Block]

	Three months ended June 30, 2015	Year ended March 31, 2015
	$	$

Fair value of non-employee options, beginning of the period	1,581,444	-
Issuance	-	767,879
Reallocation of vested non-employee options	86,261	74,190
Change in fair value of non-employee stock options during the period	178,378	739,375

Fair value of non-employee options, end of the period	1,846,083	1,581,444

Share-Based Payments Classified in the Companys Statement of Loss [Table Text Block]

	June 30, 2015	June 30, 2014
	$	$

Consulting fees	85,330	193,698
Research and development	-	50,303
Wages and salaries	224,133	94,290

	309,463	338,291

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

		March 31, 2015	March 31, 2014
Stock Price	CAD$	0.50 – 3.18	0.27
Exercise Price	CAD$	0.60 – 3.20	0.0003
Risk-free interest rate (%)		0.53 – 1.42	1.20 – 1.65
Dividend yield (%)		0.00	0.00
Expected volatility (%)		67.85	97.73 – 116.82
Expected option life (years)		3.00 – 5.00	4.33 – 5.00

Schedule of Stockholder's Equity Note Warrants Or Rights Activity [Table Text Block]

	Number of warrants				Weighted Average Exercise Price
	CAD		US		CAD $	US $
Balance, March 31, 2015	8,444,400		-	$	1.00	-
Granted	-		638,741	$	-	2.97
Exercised	(14,400	)	-	$	1.00	-
Balance, June 30, 2015	8,430,000		638,741	$	1.00	2.97

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

Number of warrants outstanding	Exercise Price	Expiry Date
8,430,000	CAD $1.00	May 30, 2016
452,032	US $3.00	April 30, 2018
167,731	US $3.00	June 26, 2018
18,978	US $2.15	June 26, 2020

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

COMMON STOCK (Narrative) (Details)	3 Months Ended
COMMON STOCK (Narrative) (Details)	Jun. 30, 2015 USD ($) $ / shares shares
Common Stock 1	$ 1,825,937
Common Stock 2 \| shares	849,273
Common Stock 3	$ 2.15
Common Stock 4 \| $ / shares	$ 3.00
Common Stock 5	$ 84,074
Common Stock 6	27,396
Common Stock 7 \| $ / shares	$ 3.00
Common Stock 8	$ 721,243
Common Stock 9 \| shares	335,463
Common Stock 10	$ 2.15
Common Stock 11 \| $ / shares	$ 3.00
Common Stock 12	$ 40,803
Common Stock 13	18,978
Common Stock 14 \| $ / shares	$ 2.15

SHARE BASED PAYMENTS (Narrative) (Details) - 3 months ended Jun. 30, 2015	USD ($) yr $ / shares shares	CAD ($) yr shares
Share Based Payments 1 \| shares	12,108,016	12,108,016
Share Based Payments 2		$ 0.54
Share Based Payments 3		1.06
Share Based Payments 4		$ 1.14
Share Based Payments 5	1.08%	1.08%
Share Based Payments 6 \| yr	4.1	4.1
Share Based Payments 7	67.85%	67.85%
Share Based Payments 8	0.00%	0.00%
Share Based Payments 9	$ 2.15
Share Based Payments 10	849,273	849,273
Share Based Payments 11	$ 1,825,937
Share Based Payments 12 \| yr	3	3
Share Based Payments 13	$ 3.00
Share Based Payments 14	27,396	27,396
Share Based Payments 15 \| $ / shares	$ 3.00
Share Based Payments 16	$ 2.15
Share Based Payments 17	335,463	335,463
Share Based Payments 18	$ 721,243
Share Based Payments 19 \| yr	3	3
Share Based Payments 20	$ 3.00
Share Based Payments 21	18,978	18,978
Share Based Payments 22 \| $ / shares	$ 2.15

COMMITMENTS AND CONTINGENCIES (Narrative) (Details)	3 Months Ended
COMMITMENTS AND CONTINGENCIES (Narrative) (Details)	Jun. 30, 2015 USD ($) mo d shares
Commitments And Contingencies 1 \| shares	16,035,026
Commitments And Contingencies 2	4.00%
Commitments And Contingencies 3	$ 499,000
Commitments And Contingencies 4	1,065,000
Commitments And Contingencies 5	1,389,000
Commitments And Contingencies 6	586,000
Commitments And Contingencies 7	$ 3,918,018
Commitments And Contingencies 8 \| mo	10
Commitments And Contingencies 9 \| d	30
Commitments And Contingencies 10	$ 300,000
Commitments And Contingencies 11	818,020
Commitments And Contingencies 12	$ 584,446

Fair Value, by Balance Sheet Grouping (Details)	3 Months Ended
Fair Value, by Balance Sheet Grouping (Details)	Jun. 30, 2015 USD ($)
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 1	$ 1,581,444
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 2	0
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 3	0
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 4	767,879
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 5	86,261
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 6	74,190
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 7	178,378
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 8	739,375
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 9	1,846,083
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 10	$ 1,581,444

Schedule of Share-based Compensation, Stock Options, Activity (Details)	3 Months Ended
	Jun. 30, 2015 CAD ($) $ / shares shares
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 1 \| shares	4,920,000
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 2 \| $ / shares	$ 1.14
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 3 \| $	$ 10,120,000
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 4 \| shares	4,920,000
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 5 \| $ / shares	$ 1.14
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 6 \| $	$ 6,676,000
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 7 \| shares	3,319,587
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 8 \| $ / shares	$ 1.16
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 9 \| $	$ 4,435,212

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award (Details)	3 Months Ended
	Jun. 30, 2015 $ / shares shares
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 1	3,520,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 2	3.97
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 3 \| $ / shares	$ 0.60
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 4 \| $ / shares	$ 0.23
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 5	2,346,669
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 6	250,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 7	3.98
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 8 \| $ / shares	$ 0.60
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 9 \| $ / shares	$ 0.23
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 10	156,250
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 11	100,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 12	2.04
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 13 \| $ / shares	$ 2.52
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 14 \| $ / shares	$ 1.06
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 15	100,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 16	450,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 17	4.44
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 18 \| $ / shares	$ 2.92
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 19 \| $ / shares	$ 1.65
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 20	450,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 21	100,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 22	4.44
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 23 \| $ / shares	$ 2.92
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 24 \| $ / shares	$ 1.49
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 25	33,334
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 26	400,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 27	4.44
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 28 \| $ / shares	$ 2.96
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 29 \| $ / shares	$ 1.56
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 30	200,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 31	100,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 32	4.72
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 33 \| $ / shares	$ 3.20
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 34 \| $ / shares	$ 1.61
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 35	33,334
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 36	4,920,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 37	3,319,587

Schedule of Non-Employee Share-based Compensation Arrangements Fair Values (Details)	3 Months Ended
	Jun. 30, 2015 USD ($)
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 1	$ 1,581,444
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 2	0
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 3	0
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 4	767,879
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 5	86,261
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 6	74,190
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 7	178,378
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 8	739,375
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 9	1,846,083
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 10	$ 1,581,444

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)	3 Months Ended
	Jun. 30, 2015 $ / shares
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 1	$ 0.50
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 2	3.18
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 3	0.27
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 4	0.60
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 5	3.20
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 6	$ 0.0003
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 7	0.53
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 8	1.42
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 9	1.20
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 10	1.65
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 11	0.00
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 12	0.00
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 13	67.85
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 14	97.73
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 15	116.82
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 16	3.00
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 17	5.00
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 18	4.33
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 19	5.00

Schedule of Stockholder's Equity Note Warrants Or Rights Activity (Details)	3 Months Ended
	Jun. 30, 2015 $ / shares shares	Jun. 30, 2015 $ / shares shares
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 1 \| shares	8,444,400	8,444,400
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 2 \| shares	0	0
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 3 \| $ / shares		$ 1.00
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 4 \| $ / shares	$ 0
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 5 \| shares	0	0
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 6 \| shares	638,741	638,741
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 7 \| $ / shares		$ 0
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 8 \| $ / shares	$ 2.97
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 9 \| shares	(14,400)	(14,400)
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 10 \| shares	0	0
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 11 \| $ / shares		$ 1.00
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 12 \| $ / shares	$ 0
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 13 \| shares	8,430,000	8,430,000
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 14 \| shares	638,741	638,741
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 15 \| $ / shares		$ 1.00
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 16 \| $ / shares	$ 2.97

Interim Condensed Consolidated Balance Sheets (Parenthetical) - shares	Jun. 30, 2015	Mar. 31, 2015
Common Stock, Shares Authorized
Common Stock, Shares, Outstanding

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)	3 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)	Jun. 30, 2015 USD ($)
Significant Accounting Policies 1	$ 3,094,854
Significant Accounting Policies 2	1,568,754
Significant Accounting Policies 3	21,574,543
Significant Accounting Policies 4	18,479,689
Significant Accounting Policies 5	971,863
Significant Accounting Policies 6	$ 418,893

CONVERTIBLE DEBENTURE (Narrative) (Details)	3 Months Ended
CONVERTIBLE DEBENTURE (Narrative) (Details)	Jun. 30, 2015 USD ($)
Convertible Debenture 1	8.00%
Convertible Debenture 2	$ 1,000,100
Convertible Debenture 3	85.00%
Convertible Debenture 4	$ 176,488

RELATED PARTY TRANSACTIONS (Narrative) (Details)	3 Months Ended
RELATED PARTY TRANSACTIONS (Narrative) (Details)	Jun. 30, 2015 USD ($)
Related Party Transactions 1	$ 40,160
Related Party Transactions 2	1,000
Related Party Transactions 3	30,491
Related Party Transactions 4	$ 0

SUBSEQUENT EVENTS (Narrative) (Details)	3 Months Ended
SUBSEQUENT EVENTS (Narrative) (Details)	Jun. 30, 2015 USD ($) $ / shares shares
Subsequent Events 1	$ 270,375
Subsequent Events 2 \| shares	125,756
Subsequent Events 3	$ 2.15
Subsequent Events 4 \| $ / shares	$ 3.00
Subsequent Events 5	$ 16,223
Subsequent Events 6	7,545
Subsequent Events 7 \| $ / shares	$ 2.15

Share-Based Payments Classified in the Companys Statement of Loss (Details)	3 Months Ended
	Jun. 30, 2015 USD ($)
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 1	$ 85,330
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 2	193,698
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 3	0
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 4	50,303
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 5	224,133
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 6	94,290
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 7	309,463
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 8	$ 338,291